Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease
NCT00529035
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
29
Enrollment
OTHER
Sponsor class
Conditions
Graft Versus Host Disease
Interventions
DRUG:
Interleukin-2
Sponsor
Dana-Farber Cancer Institute
Collaborators
[object Object]
[object Object]